why choose us

First received: October 05, 2023

Clinical Trial: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neoplasms

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Nirapari

Brief Summary: The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc).The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Read more